OncoMatch/Clinical Trials/NCT06451497
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Is NCT06451497 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies ZM008 for non small cell lung cancer.
Treatment: ZM008 — This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are intolerant of the same.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Head and Neck Squamous Cell Carcinoma
Pancreatic Cancer
Cholangiocarcinoma
Prostate Cancer
Urothelial Carcinoma
Colorectal Cancer
Triple-Negative Breast Cancer
Breast Carcinoma
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Renal Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: immune checkpoint inhibitor
Exception: patients who discontinued prior treatment with any immune checkpoint due to immune-related aes, irrespective of grade, recovery, or need for continued steroid therapy
Cannot have received: allogeneic bone marrow transplantation
Cannot have received: solid organ transplantation
Lab requirements
Blood counts
hemoglobin ≥9 g/dl (no transfusions in previous 2 weeks); anc ≥1.0 × 10^9/l (no growth factors in previous 2 weeks); platelet count ≥75 × 10^9/l (no transfusions in previous 2 weeks)
Kidney function
estimated creatinine clearance (crcl) ≥30 ml/minute (cockcroft-gault formula)
Liver function
total bilirubin ≤1.5x uln; ast/alt ≤3.0x uln (≤5.0x uln if liver metastases present)
Cardiac function
qtc (fridericia) ≤470 msec in patients without pacemaker; uncontrolled or significant cardiovascular disease defined as nyha iii or iv excluded
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dana Farber Cancer Institute · Boston, Massachusetts
- NEXT Oncology · Austin, TX 78758, Texas
- NEXT Oncology · San Antonio, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06451497 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immune checkpoint inhibitor, allogeneic bone marrow transplantation, solid organ transplantation disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify